MONROVIA, Calif.--(BUSINESS WIRE)--May 2, 2019--
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company
developing engineered monoclonal antibodies for the treatment of cancer,
autoimmune diseases, asthma and allergic diseases, today announced that
it will release first quarter 2019 financial results after the market
closes on Thursday, May 9, 2019.
Xencor management will host a webcast and conference call the same day
at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and
provide a corporate update.
The live call may be accessed by dialing (877) 359-9508 for domestic
callers or (224) 357-2393 for international callers and referencing
conference ID number 8597541. A live webcast of the conference call will
be available under "Events & Presentations" in the Investors section of
the Company's website located at www.xencor.com.
The webcast will be archived on the company website for 90 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing
engineered monoclonal antibodies for the treatment of cancer, autoimmune
diseases, asthma and allergic diseases. Currently, 12 candidates
engineered with Xencor's XmAb® technology are in
clinical development internally and with partners. Xencor's XmAb
antibody engineering technology enables small changes to the structure
of monoclonal antibodies resulting in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005852/en/
Source: Xencor, Inc.
Jason I. Spark